MET and non-small cell lung carcinoma: Although crizotinib has been known as a potent ALK inhibitor that has been approved by the FDA for patients with advanced ALK-positive NSCLC [27], it also inhibits various tyrosine kinases, including ROS1, c-Met, and RON kinases [38].